FI952119A0 - Stabiili pakastekuivattu koostumus, joka sisältää proteiinia ja testipakkaus - Google Patents

Stabiili pakastekuivattu koostumus, joka sisältää proteiinia ja testipakkaus

Info

Publication number
FI952119A0
FI952119A0 FI952119A FI952119A FI952119A0 FI 952119 A0 FI952119 A0 FI 952119A0 FI 952119 A FI952119 A FI 952119A FI 952119 A FI952119 A FI 952119A FI 952119 A0 FI952119 A0 FI 952119A0
Authority
FI
Finland
Prior art keywords
test kit
composition containing
containing protein
lyophilized composition
stable lyophilized
Prior art date
Application number
FI952119A
Other languages
English (en)
Swedish (sv)
Other versions
FI117321B (fi
FI952119A (fi
Inventor
Alain Bayol
Thierry Breul
Patrice Dupin
Philippe Faure
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of FI952119A0 publication Critical patent/FI952119A0/fi
Publication of FI952119A publication Critical patent/FI952119A/fi
Application granted granted Critical
Publication of FI117321B publication Critical patent/FI117321B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI952119A 1994-05-04 1995-05-03 Stabiili pakastekuivattu koostumus, joka sisältää proteiinia ja testipakkaus FI117321B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9405486A FR2719479B1 (fr) 1994-05-04 1994-05-04 Formulation stable lyophilisée comprenant une protéine: kit de dosage.
FR9405486 1994-05-04

Publications (3)

Publication Number Publication Date
FI952119A0 true FI952119A0 (fi) 1995-05-03
FI952119A FI952119A (fi) 1995-11-05
FI117321B FI117321B (fi) 2006-09-15

Family

ID=9462880

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952119A FI117321B (fi) 1994-05-04 1995-05-03 Stabiili pakastekuivattu koostumus, joka sisältää proteiinia ja testipakkaus

Country Status (25)

Country Link
US (1) US5763409A (fi)
EP (1) EP0682944B1 (fi)
JP (1) JP2948125B2 (fi)
KR (1) KR100273053B1 (fi)
CN (1) CN1088583C (fi)
AT (1) ATE178484T1 (fi)
AU (1) AU694763B2 (fi)
CA (1) CA2148537C (fi)
CZ (1) CZ286195B6 (fi)
DE (1) DE69508837T2 (fi)
DK (1) DK0682944T3 (fi)
ES (1) ES2131781T3 (fi)
FI (1) FI117321B (fi)
FR (1) FR2719479B1 (fi)
GR (1) GR3030146T3 (fi)
HU (1) HU220220B (fi)
IL (1) IL113578A (fi)
MX (1) MX9502034A (fi)
NO (1) NO320364B1 (fi)
NZ (1) NZ272045A (fi)
PL (1) PL179240B1 (fi)
RU (1) RU2136306C1 (fi)
SI (1) SI0682944T1 (fi)
TW (1) TW397687B (fi)
ZA (1) ZA953596B (fi)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CN1151842C (zh) * 1995-07-27 2004-06-02 基因技术股份有限公司 稳定等渗的冻干蛋白制剂
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
FR2768341B1 (fr) 1997-09-18 2000-04-14 Lab Francais Du Fractionnement Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
EP0913177A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
EP0913178A1 (en) * 1997-11-03 1999-05-06 Boehringer Mannheim Gmbh Process for the manufacture of dry, amorphous products comprising biologically active material by means of convection drying and products obtainable by the process
EP1071465A1 (en) * 1998-03-18 2001-01-31 Ronai, Peter Amorphous glasses for stabilising sensitive products
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
YU31902A (sh) * 1999-10-28 2004-12-31 Institut Neftekhimicheskogo Sinteza Imeni A.V.Topchieva Rossiiskoi Akademii Nauk Polipeptidna kompozicija
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
CA2428144C (en) * 2000-11-07 2012-01-10 Chiron Corporation Compositions of interferon-beta stabilized with highly purified mannitol
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
CA2464250C (en) * 2001-10-24 2008-08-05 Frank-Christophe Lintz Kit for the preparation of a pharmaceutical composition
WO2003097237A2 (en) 2002-05-13 2003-11-27 Becton, Dickinson, And Company Protease inhibitor sample collection system
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
PT1589949E (pt) * 2003-01-08 2008-11-06 Novartis Vaccines & Diagnostic Composições liofilizadas estabilizadas compreendendo inibidor da coagulação por factores tecidulares ou variante de inibidor da coagulação por factores tecidulares
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
US11229746B2 (en) 2006-06-22 2022-01-25 Excelsior Medical Corporation Antiseptic cap
EP2535058A3 (en) * 2006-11-07 2013-04-10 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
WO2009002521A2 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
US9078992B2 (en) 2008-10-27 2015-07-14 Pursuit Vascular, Inc. Medical device for applying antimicrobial to proximal end of catheter
CA2742328C (en) 2008-11-07 2019-02-26 Baxter International Inc. Factor viii formulations
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
JP2013510158A (ja) * 2009-11-03 2013-03-21 グリフオルス・セラピユーテイクス・インコーポレーテツド α‐１プロテイナーゼインヒビターのための組成物、方法およびキット
JP6007105B2 (ja) * 2009-12-22 2016-10-12 セルデックス・セラピューティクス・インコーポレイテッド ワクチン組成物
RU2448156C1 (ru) * 2011-03-17 2012-04-20 Эспосито Трейдинг Лтд Способ получения лиофилизированной субстанции
RU2448158C1 (ru) * 2011-03-24 2012-04-20 Эспосито Трейдинг Лтд Способ получения препарата фортелизин, обладающего фибринолитическими свойствами, и его применение для лечения инфаркта миокарда
EP3714932A1 (en) 2011-07-12 2020-09-30 ICU Medical, Inc. Device for delivery of antimicrobial agent into a transdermal catheter
JP6226872B2 (ja) * 2011-11-22 2017-11-08 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． キャリブレーションおよび／またはクオリティ・コントロール溶液として再構成用の乾燥試薬を含むデバイスとその製造および使用方法
US20140017318A1 (en) * 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CN105848645A (zh) 2013-09-27 2016-08-10 韩美药品株式会社 持续型人生长激素制剂
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
JP6822978B2 (ja) 2015-05-08 2021-01-27 アイシーユー・メディカル・インコーポレーテッド 治療薬のエミッタを受け入れるように構成された医療用コネクタ
ES2671844B1 (es) 2015-06-11 2019-03-22 Attwill Medical Solutions Inc Dispositivos médicos, sistemas y métodos que utilizan composiciones de anti-trombina heparina.
PT3525865T (pt) 2016-10-14 2022-11-17 Icu Medical Inc Tampas de higienização para conectores médicos
WO2018204206A2 (en) 2017-05-01 2018-11-08 Icu Medical, Inc. Medical fluid connectors and methods for providing additives in medical fluid lines
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
US11541220B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Needleless connector with antimicrobial properties
US11534595B2 (en) 2018-11-07 2022-12-27 Icu Medical, Inc. Device for delivering an antimicrobial composition into an infusion device
US11541221B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Tubing set with antimicrobial properties
US11400195B2 (en) 2018-11-07 2022-08-02 Icu Medical, Inc. Peritoneal dialysis transfer set with antimicrobial properties
US11517732B2 (en) 2018-11-07 2022-12-06 Icu Medical, Inc. Syringe with antimicrobial properties
AU2019384564B2 (en) 2018-11-21 2023-11-23 Icu Medical, Inc. Antimicrobial device comprising a cap with ring and insert
EP4255552A1 (en) 2020-12-07 2023-10-11 ICU Medical, Inc. Peritoneal dialysis caps, systems and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5822445B2 (ja) * 1982-07-08 1983-05-09 株式会社 ミドリ十字 安定な固体の人血漿コリンエステラ−ゼ製剤の製法
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0296536A (ja) * 1988-09-29 1990-04-09 Green Cross Corp:The プラスミノゲン乾燥製剤
EP0437662B1 (de) * 1990-01-18 1994-09-14 Cereria Amos Sgarbi S.P.A. Grablicht
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung

Also Published As

Publication number Publication date
US5763409A (en) 1998-06-09
PL179240B1 (pl) 2000-08-31
NO951724D0 (no) 1995-05-03
KR100273053B1 (ko) 2000-12-01
IL113578A (en) 1999-10-28
HUT72325A (en) 1996-04-29
CA2148537A1 (en) 1995-11-05
AU1777495A (en) 1995-11-16
HU220220B (hu) 2001-11-28
MX9502034A (es) 1997-02-28
CA2148537C (en) 2002-07-16
CZ286195B6 (cs) 2000-02-16
JPH0853361A (ja) 1996-02-27
FI117321B (fi) 2006-09-15
CN1116522A (zh) 1996-02-14
FR2719479A1 (fr) 1995-11-10
AU694763B2 (en) 1998-07-30
ATE178484T1 (de) 1999-04-15
KR950031103A (ko) 1995-12-18
DE69508837D1 (de) 1999-05-12
JP2948125B2 (ja) 1999-09-13
DE69508837T2 (de) 1999-11-04
IL113578A0 (en) 1995-08-31
FR2719479B1 (fr) 1996-07-26
CZ108195A3 (en) 1996-02-14
SI0682944T1 (en) 1999-08-31
NO951724L (no) 1995-11-06
FI952119A (fi) 1995-11-05
PL308416A1 (en) 1995-11-13
NO320364B1 (no) 2005-11-28
EP0682944A1 (fr) 1995-11-22
GR3030146T3 (en) 1999-08-31
EP0682944B1 (fr) 1999-04-07
HU9501276D0 (en) 1995-06-28
ES2131781T3 (es) 1999-08-01
NZ272045A (en) 1996-02-27
TW397687B (en) 2000-07-11
RU2136306C1 (ru) 1999-09-10
DK0682944T3 (da) 1999-10-18
CN1088583C (zh) 2002-08-07
ZA953596B (en) 1996-11-04

Similar Documents

Publication Publication Date Title
FI952119A (fi) Stabiili pakastekuivattu koostumus, joka sisältää proteiinia ja testipakkaus
DK0732935T3 (da) Lyofiliserede stamcellefaktorformuleringer
TR24655A (tr) Karbon isleri ve karbon islerini iceren kaucuk bilesimleri
DE3778287D1 (de) Peptidische zusammensetzung.
HRP20000181B1 (en) 2-methyl-thieno-benzodiazepine formulation
MX164233B (es) Composicion de caucho modificada con nylon
NO921256D0 (no) Aminosyre-beta-lyaseenzyminhibitor som deodoranter
MC1884A1 (fr) Variants de l'hirudine,leur utilisation et leur preparation
NO944256L (no) Stabil, lyofilisert tiotepablanding
FI864795A0 (fi) Komposition innehaollande primicin.
RS49691B (sr) Liofilizovan preparat ljudskog morfogenetskog faktora mp52 kosti
DE69008009T2 (de) Harte Gummizusammensetzung.
DK1612555T3 (da) Kryptiske peptider til anvendelse til at inducere immunologisk tolerance
ATE80143T1 (de) Isomere formyl-trimethylbicyclo(2,2,2)oct-7-ene.
RU1839630C (ru) Лыжна палка
ATE74764T1 (de) Peptidische zusammensetzung.
PH30431A (en) N-(aryloxyalkyl) heteroarylpiperidines and heteroarylpiperazines and their use as antipsychotics

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: SANOFI-AVENTIS

FG Patent granted

Ref document number: 117321

Country of ref document: FI

MA Patent expired